Unresectable Melanoma Clinical Trials

11 recruiting

Unresectable Melanoma Trials at a Glance

13 actively recruiting trials for unresectable melanoma are listed on ClinicalTrialsFinder across 6 cities in 14 countries. The largest study group is Phase 2 with 10 trials, with the heaviest enrollment activity in Los Angeles, San Francisco, and New York. Lead sponsors running unresectable melanoma studies include Iovance Biotherapeutics, Inc., National Cancer Institute (NCI), and Linnaeus Therapeutics, Inc..

Browse unresectable melanoma trials by phase

Treatments under study

About Unresectable Melanoma Clinical Trials

Looking for clinical trials for Unresectable Melanoma? There are currently 11 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Unresectable Melanoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Unresectable Melanoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 113 of 13 trials

Recruiting
Phase 1Phase 2

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Melanoma+10 more
National Cancer Institute (NCI)16 enrolled26 locationsNCT05896839
Recruiting
Phase 2

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Head and Neck Squamous Cell Carcinoma+22 more
National Cancer Institute (NCI)150 enrolled221 locationsNCT05136196
Recruiting
Phase 2Phase 3

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

Unresectable MelanomaCutaneous MelanomaMelanoma (Skin Cancer)+1 more
Linnaeus Therapeutics, Inc.135 enrolled9 locationsNCT06624644
Recruiting
Phase 3

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

MelanomaMetastatic MelanomaUnresectable Melanoma
Iovance Biotherapeutics, Inc.670 enrolled75 locationsNCT05727904
Recruiting
Phase 2

Prebiotic Food-enriched Diet (PreFED) to Enhance the Microbiome and Response to First-line Immunotherapy in Unresectable Melanoma

Unresectable Melanoma
M.D. Anderson Cancer Center75 enrolled1 locationNCT06466434
Recruiting
Phase 1Phase 2

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+97 more
Mayo Clinic132 enrolled1 locationNCT05269381
Recruiting

Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients

MelanomaUnresectable MelanomaMelanoma Stage IV+1 more
University of Wisconsin, Madison24 enrolled1 locationNCT06199713
Recruiting
Phase 2

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma

Metastatic MelanomaUnresectable MelanomaMelanoma (Skin Cancer)
Iovance Biotherapeutics, Inc.100 enrolled5 locationsNCT07288203
Recruiting
Phase 2

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

MelanomaUnresectable Melanoma
NYU Langone Health105 enrolled4 locationsNCT05428007
Recruiting
Phase 1Phase 2

A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel

Metastatic MelanomaUnresectable MelanomaOcular Melanoma
Iovance Biotherapeutics, Inc.42 enrolled4 locationsNCT06940739
Recruiting
Phase 2

Mirdametinib in Patients With Advanced NF1-mutant Melanoma

Metastatic MelanomaAdvanced Unresectable Melanoma
Kevin Kim, MD10 enrolled1 locationNCT07237100
Recruiting
Phase 1

A Study of NX-1607 in Adults With Advanced Malignancies

Gastric CancerNon-small Cell Lung Cancer (NSCLC)Head and Neck Squamous Cell Carcinoma+5 more
Nurix Therapeutics, Inc.345 enrolled17 locationsNCT05107674
Recruiting
Phase 1Phase 2

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

Metastatic MelanomaUnresectable MelanomaStage III Non-small Cell Lung Cancer
Iovance Biotherapeutics, Inc.53 enrolled10 locationsNCT05361174